mTOR and tyrosine kinase inhibitors may play an increasing role in the management of well-differentiated neuroendocrine tumors in the future. Peptide receptor radiotherapy is a new treatment ...
IL-2 and IL-15 receptor complexes share the β and γ chains ... MAPK/ERK and PI3K/Akt/mTOR. Recent studies have identified that the IL-2/IL-2R signaling pathway is an essential target to treat ...
GlobalData on MSN7d
Novartis and Olema expand alliance with $250m to boost breast cancer trialsOlema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback